Bupropion-Dextromethorphan Dosing for Renal Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for neurological and psychiatric conditions, particularly major depressive disorder, face challenges in managing adverse effects such as somnolence and dizziness, especially in patients with moderate renal impairment, and require careful consideration of drug interactions with CYP2D6 inhibitors.
Innovation Solution
Administer a combination of bupropion hydrochloride and dextromethorphan hydrobromide in specific dosages and schedules tailored to the patient's renal function and CYP2D6 status, adjusting dosing to minimize adverse effects and optimize therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard dosing of dextromethorphan and bupropion is administered to patients with moderate renal impairment, then therapeutic efficacy is achieved, but the risk of somnolence and dizziness increases
Solution Approach 1:
The patent modifies the dosing parameters (frequency and/or dose) of dextromethorphan and bupropion specifically for patients with moderate renal impairment. This parameter adjustment reduces plasma concentrations to lower the risk of somnolence and dizziness while maintaining therapeutic efficacy for neurological and psychiatric conditions.
2Reliability
If dextromethorphan is co-administered with CYP2D6 inhibitors, then treatment of neurological conditions is achieved, but drug interactions increase dextromethorphan exposure
Solution Approach 1:
The patent adjusts dosing parameters when dextromethorphan is co-administered with CYP2D6 inhibitors to account for reduced metabolism. This prevents excessive accumulation of dextromethorphan in plasma while maintaining effective treatment levels for neurological and psychiatric conditions.
3Duration of action of moving object
If dextromethorphan and bupropion are administered twice daily, then therapeutic coverage is optimized, but adverse effects increase in renal impairment patients
Solution Approach 1:
The patent modifies the periodic administration schedule from twice daily to once daily (or adjusted frequency) for patients with moderate renal impairment. This reduced periodic dosing maintains adequate therapeutic coverage while lowering cumulative exposure and reducing the incidence of adverse effects such as somnolence and dizziness.
Data Source
AI summary
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.